- Conditions
- Blood Glucose
- Interventions
- D-allulose, sucrose, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Suramin Drug:Docetaxel Drug: Carboplatin, Placebo Drug: Docetaxel Drug: Carboplatin
- Drug
- Lead sponsor
- Optimum Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Richmond, Virginia
- Conditions
- Post-Exercise Hypotension
- Interventions
- Moderate Intensity Aerobic Exercise
- Other
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Alzheimer Disease
- Interventions
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos
- Drug
- Lead sponsor
- T3D Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes Mellitus, Type 2, Acute Coronary Syndrome
- Interventions
- Alogliptin, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
- Conditions
- Metabolic Syndrome
- Interventions
- Sildenafil citrate, Placebo Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Obesity
- Interventions
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Exercise Physiology, Nutritional Supplementation
- Interventions
- Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage
- Dietary Supplement · Other
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Obesity, Insulin Resistance, Insulin Sensitivity, Beta-Cell Dysfunction, Prediabetes
- Interventions
- Placebo, Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d), High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
- Interventions
- PZ-128, Placebo
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
- Conditions
- Epilepsy
- Interventions
- Empagliflozin 25 mg, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Schizophrenia
- Interventions
- sodium nitroprusside, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more
- Conditions
- Physical Endurance
- Interventions
- Beta-alanine, Placebo, Muscular endurance exercise
- Dietary Supplement · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin 9, 39, Placebo
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- Empagliflozin 10 mg Tab, Placebo Oral Tablet
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 19 Years to 119 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more
- Conditions
- Type 1 Diabetes, Hypoglycemia
- Interventions
- Beta-hydroxybutyrate, Normal Saline
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo Attention Control, Supervised Exercise Training
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- BIIB092, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
- Conditions
- Heart Transplant, Cardiovascular Disease, Kidney Disease
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Nashville, Tennessee • Houston, Texas + 3 more
- Conditions
- Intestinal Health
- Interventions
- "Humanized" galacto-oligosaccharides (hGOS), Galacto-oligosaccharides (GOS), Matching Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Eustachian Tube Dysfunction
- Interventions
- Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
- Drug · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
- Conditions
- Traumatic Brain Injury
- Interventions
- PNT001, %5 dextrose for infusion
- Biological
- Lead sponsor
- Pinteon Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania